Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer.

Study reveals how a new IgE antibody therapy reactivates immune cells, offering a promising approach to fighting ovarian ...

Epsilogen has acquired antibody developer TigaTx in a deal that collates work from the companies’ alternative antibody isotopes for cancer.

an anti-Folate Receptorα IgE antibody, currently in a Phase Ib Proof of Concept trial in platinum-resistant ovarian cancer. Data from a Phase I trial found it to be safe and well tolerated with ...

Epsilogen, the global leader in the development of immunoglobulin E (IgE) antibody therapeutics, today announces that it has completed the acquisition of TigaTx, Inc., a biotechnology company ...

Epsilogen completes acquisition of TigaTx to create world’s leading pan-isotype cancer antibody company: London Tuesday, April 8, 2025, 10:00 Hrs [IST] Epsilogen, the global lea ...